<DOC>
	<DOCNO>NCT00003907</DOCNO>
	<brief_summary>RATIONALE : Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . PURPOSE : Phase II trial study effectiveness chemoembolization treat patient primary liver cancer metastases liver surgically remove .</brief_summary>
	<brief_title>Chemoembolization Treating Patients With Primary Liver Cancer Metastases Liver</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate time progression disease patient unresectable hepatocellular carcinoma neuroendocrine hepatic metastasis undergo chemoembolization . - Evaluate tumor response achievable chemoembolization patient population . - Evaluate toxicity treatment patient . - Evaluate survival patient follow treatment . - Evaluate extrahepatic pattern failure follow chemoembolization , determine whether intrahepatic progression may forestall survival affected patient . - Validate consistent method perform chemoembolization multicenter set . OUTLINE : Patients stratify accord disease ( hepatocellular carcinoma v neuroendocrine hepatic metastasis ) . Patients undergo placement visceral arterial catheter . Patients receive doxorubicin , mitomycin , cisplatin chemoemulsion via arterial catheter 1 hepatic lobe . Immediately follow delivery chemoemulsion , particulate embolization perform . The opposite lobe , involve , treat within 3-5 week treatment initial lobe . In absence unacceptable toxicity , involve lobe treat separately second time , sequence , begin 8 week last lobular chemoembolization . After completion protocol therapy , retreatment study either lobe allow regrowth , recurrence , new disease , provide least 3 month elapse since initial treatment lobe . Patients follow 5 year . PROJECTED ACCRUAL : A total 19-42 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>Biopsyproven intrahepatic hepatocellular carcinoma neuroendocrine tumor . Unresectable . Bidimensionally measurable disease Computed Tomography ( CT ) , Magnetic resonance imaging ( MRI ) , UltraSound Scanning ( US ) within 6 week registration . Evidence patent portal vasculature Doppler US , MRI , angiography . Serum total bilirubin &lt; 2.0 mg/dl serum creatinine &lt; 2.0 mg/dl within 4 week registration . Absolute neutrophil count ( ANC ) &gt; 2000/µl platelet &gt; 50,000/µl within 4 week registration . Expected survival least 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Age &gt; = 18 year . Evidence extrahepatic disease likely lifethreatening within 3 month , brain symptomatic lung metastasis . Previous intraarterial intrahepatic chemotherapy prior systemic chemotherapy within 4 week . Concurrent malignancy . Pregnant breastfeed woman . History lifethreatening contrast allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>liver metastasis</keyword>
</DOC>